GlassScriptPhysician profile
Adam B Aronson
NPI 1629465778
$2,211.91
in general payments reported to CMS, 2019-2025
21 companies · $340 in 2025
The $340 reported for 2025 was less than what a typical Mohs-Micrographic Surgery provider received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $265 · 2020: $191 · 2021: $165 · 2022: $614 · 2023: $426 · 2024: $210 · 2025: $340.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $961 · Education: $15.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $960.93 |
| Education | $15.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $383.46 | 2021-2025 | Rinvoq, Botox |
| Galderma Laboratories, L.P. | $286.07 | 2021-2025 | |
| Allergan, INC. | $174.17 | 2022 | |
| Epi Health, LLC | $142.18 | 2020-2022 | |
| Sun Pharmaceutical Industries INC. | $129.60 | 2021-2025 | |
| Glaxosmithkline, LLC. | $127.22 | 2021-2024 | Pediarix, Bexsero |
| Genzyme Corporation | $122.11 | 2023 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $116.32 | 2019-2020 | |
| Pfizer INC. | $110.37 | 2023-2024 | |
| Janssen Biotech, INC. | $100.09 | 2020-2025 | Tremfya |
| Amgen INC. | $94.76 | 2020-2024 | Otezla |
| Organogenesis INC. | $72.53 | 2025 | Simplimax |
| Celgene Corporation | $65.10 | 2019 | |
| Almirall LLC | $57.11 | 2019 | |
| Vyne Pharmaceuticals INC. | $46.01 | 2020-2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $46.00 | 2023-2025 | Libtayo |
| Regeneron Pharmaceuticals, INC. | $45.00 | 2019 | |
| Ucb, INC. | $24.31 | 2024 | Bimzelx |
| Revance Therapeutics, INC. | $23.78 | 2025 | Daxxify |
| Sanofi-Aventis U.S. LLC | $23.60 | 2020 | |
| Lilly USA, LLC | $22.12 | 2024 | Taltz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Aronson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.